ArticleThorax2002
Peripheral airway obstruction in primary pulmonary hypertension.
Article in Thorax, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02108743 (Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Who cites it
45 citing papers in PubMed, 178 citations in OpenAlex.
- Trial
- Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.Respiratory research · 2009Trial
- Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma.The Journal of allergy and clinical immunology · 2008Trial
- Challenges and Strategies in Managing Pulmonary Arterial Hypertension Within the Indian Healthcare System: A Consensus Statement From the Pulmonary Vascular Research Institute India Taskforce.Pulmonary circulation · 2026Article
- Sotatercept Improves Small Airway Disease and Hyperinflation in Patients with Pulmonary Hypertension.medRxiv : the preprint server for health sciences · 2025Article
- Lung Single-Cell Transcriptomics Reveal Diverging Pathobiology and Opportunities for Precision Targeting in Scleroderma-Associated Versus Idiopathic Pulmonary Arterial Hypertension.Circulation. Genomic and precision medicine · 2025Article
- Pulmonary function impairment and its relationship with target therapy response in patients with pulmonary arterial hypertension.Frontiers in medicine · 2025Article
- Significance of Normal Lung Volume on Quantitative CT Imaging Analysis in Group 1 and Group 3 Pulmonary Hypertension.CHEST pulmonary · 2024Article
- 2023 TSOC-TACVPR-TACPAH Consensus Statement of the Rehabilitation on Patients with Pulmonary Hypertension.Acta Cardiologica Sinica · 2024Article
- Pulmonary hypertension in adults with congenital heart defects (ACHDs)-in light of the 2022 ESC PAH guidelines-part I: definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, gender aspects.Cardiovascular diagnosis and therapy · 2024Review
- Definition, classification and diagnosis of pulmonary hypertension.The European respiratory journal · 2024Article
- Fractional exhaled nitric oxide in idiopathic pulmonary arterial hypertension and mixed connective tissue disease complicating pulmonary hypertension.BMC pulmonary medicine · 2024Article
- Predictors of early mortality after lung transplantation for idiopathic pulmonary arterial hypertension.Pulmonary circulation · 2024Article
- Impulse oscillometry in patients with pulmonary arterial hypertension: an exploratory study.Clinics (Sao Paulo, Brazil) · 2024Article
- The Current Role of Cardiopulmonary Exercise Test in the Diagnosis and Management of Pulmonary Hypertension.Journal of clinical medicine · 2023Review
- Cross-sectional Study of Workers Employed at a Copper Smelter-Effects of Long-term Exposures to Copper on Lung Function and Chronic Inflammation.Journal of occupational and environmental medicine · 2022Article
- Article
- The physiological basis of pulmonary arterial hypertension.The European respiratory journal · 2022Review
- Clinical characteristics associated with small airways disease in systemic sclerosis.Journal of scleroderma and related disorders · 2022Article
- Association of nutritional status and mortality risk in patients with primary pulmonary hypertension.Pulmonary circulation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs there is controversy about changes in lung function in primary pulmonary hypertension (PPH), lung mechanics were assessed with a focus on expiratory airflow in relation to pulmonary haemodynamics.
methodsA cross sectional study was performed in 64 controls and 171 patients with PPH (117 women) of mean (SD) age 45 (13) years, pulmonary artery pressure (PAPmean) 57 (15) mm Hg, and pulmonary vascular resistance 1371 (644) dyne.s/cm(5).
resultsMean (SD) total lung capacity was similar in patients with PPH and controls (98 (12)% predicted v 102 (17)% predicted, mean difference -4 (95% confidence interval (CI) -7.89 to -0.11); residual volume (RV) was increased (118 (24)% predicted v 109 (27)% predicted, mean difference 9 (95% CI 1.86 to 16.14); and vital capacity (VC) was decreased (91 (16)% predicted v 102 (10)% predicted, mean difference -11 (95% CI 15.19 to -6.80). RV/TLC was increased (117 (27)% predicted v 97 (29)% predicted, mean difference 20 (95% CI 12.3 to 27.8)) and correlated with PAPmean (r=0.31, p<0.001). In patients with PAPmean above the median of 56 mm Hg, RV/TLC was further increased (125 (32)% predicted v 111 (22)% predicted, mean difference -14 (95% CI -22.2 to -5.8)). Expiratory flow-volume curves were reduced and curvilinear in patients with PPH.
conclusionsPeripheral airway obstruction is common in PPH and is more pronounced in severe disease. This may contribute to symptoms. Reversibility of bronchodilation and relation to exercise capacity need further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.